Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Movement Disorders Channel:
Huntington's Disease

Welcome to The Huntington’s Disease Channel

VJNeurology brings you the latest updates in Huntington’s disease directly from world-leading experts. The Huntington’s Disease Channel brings you video interviews from international conferences.

Discover key developments in this space, including updates in disease biology, novel treatment strategies, and ongoing clinical trials.

Targeting dysregulated axonal transport in Huntington’s disease 2:03
Targeting dysregulated axonal transport in Huntington’s disease
Frederic Saudou • 20 Sep 2022
Huntingtin lowering: what level of wildtype protein knockdown is safe? 2:21
Huntingtin lowering: what level of wildtype protein knockdown is safe?
Michael Hayden • 27 Sep 2022
Strategies to improve ASOs in Huntington’s disease 1:56
Strategies to improve ASOs in Huntington’s disease
Patrick Weydt • 23 Sep 2022
NfL as a potential biomarker for juvenile onset Huntington’s disease 3:32
NfL as a potential biomarker for juvenile onset Huntington’s disease
Lauren Byrne • 23 Sep 2022
EHDN 2022 meeting highlights 1:34
EHDN 2022 meeting highlights
Patrick Weydt • 23 Sep 2022
How does huntingtin regulate neuronal transport? 2:32
How does huntingtin regulate neuronal transport?
Frederic Saudou • 20 Sep 2022
Somatic expansion as a novel therapeutic approach for Huntington’s disease 2:54
Somatic expansion as a novel therapeutic approach for Huntington’s disease
Michael Hayden • 27 Sep 2022
Pridopidine rescues BDNF transport in a Huntington’s disease brain-on-a-chip model 3:25
Pridopidine rescues BDNF transport in a Huntington’s disease brain-on-a-chip model
Frederic Saudou • 20 Sep 2022
The role of post-translational modifications in Huntington’s disease 2:22
The role of post-translational modifications in Huntington’s disease
Michael Hayden • 27 Sep 2022
Phase II study of ANX005 in patients with Huntington’s disease 3:49
Phase II study of ANX005 in patients with Huntington’s disease
Ann Morgan et al. • 16 Sep 2022
Digital tools in Huntington’s disease clinical trials 1:50
Digital tools in Huntington’s disease clinical trials
Patrick Weydt • 23 Sep 2022
Moving forwards after disappointing data in the Huntington’s disease space 1:05
Moving forwards after disappointing data in the Huntington’s disease space
Patrick Weydt • 23 Sep 2022
Biomarkers for therapeutic development in Huntington’s disease 3:47
Biomarkers for therapeutic development in Huntington’s disease
Lauren Byrne • 23 Sep 2022
Biofluid biomarkers in Huntington’s disease: mHTT and NfL 3:07
Biofluid biomarkers in Huntington’s disease: mHTT and NfL
Lauren Byrne • 23 Sep 2022
NMDA receptor modulation as a novel therapeutic mechanism in Huntington’s disease 2:31
NMDA receptor modulation as a novel therapeutic mechanism in Huntington’s disease
Aaron Koenig • 22 Sep 2022
ASO versus AAV gene therapy strategies in Huntington’s disease 2:07
ASO versus AAV gene therapy strategies in Huntington’s disease
Patrick Weydt • 23 Sep 2022
The content of VJNeurology is intended for healthcare professionals